These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28881567)

  • 1. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.
    Davis DA; Mishra S; Anagho HA; Aisabor AI; Shrestha P; Wang V; Takamatsu Y; Maeda K; Mitsuya H; Zeldis JB; Yarchoan R
    Oncotarget; 2017 Aug; 8(31):50342-50358. PubMed ID: 28881567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.
    Davis DA; Shrestha P; Aisabor AI; Stream A; Galli V; Pise-Masison CA; Tagawa T; Ziegelbauer JM; Franchini G; Yarchoan R
    Oncoimmunology; 2019; 8(2):e1546544. PubMed ID: 30713808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.
    Wu Y; Shrestha P; Heape NM; Yarchoan R
    J Transl Med; 2022 May; 20(1):217. PubMed ID: 35562811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
    Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
    PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.
    Ishido S; Wang C; Lee BS; Cohen GB; Jung JU
    J Virol; 2000 Jun; 74(11):5300-9. PubMed ID: 10799607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.
    Tomescu C; Law WK; Kedes DH
    J Virol; 2003 Sep; 77(17):9669-84. PubMed ID: 12915579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
    Smith CG; Kharkwal H; Wilson DW
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
    Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
    J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.
    Host KM; Jacobs SR; West JA; Zhang Z; Costantini LM; Stopford CM; Dittmer DP; Damania B
    mBio; 2017 Oct; 8(5):. PubMed ID: 29018115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.
    Rimessi P; Bonaccorsi A; Stürzl M; Fabris M; Brocca-Cofano E; Caputo A; Melucci-Vigo G; Falchi M; Cafaro A; Cassai E; Ensoli B; Monini P
    J Virol; 2001 Aug; 75(15):7161-74. PubMed ID: 11435597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein.
    Ishido S; Choi JK; Lee BS; Wang C; DeMaria M; Johnson RP; Cohen GB; Jung JU
    Immunity; 2000 Sep; 13(3):365-74. PubMed ID: 11021534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus.
    Brander C; Suscovich T; Lee Y; Nguyen PT; O'Connor P; Seebach J; Jones NG; van Gorder M; Walker BD; Scadden DT
    J Immunol; 2000 Aug; 165(4):2077-83. PubMed ID: 10925292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.
    Mohanty S; Kumar A; Das P; Sahu SK; Choudhuri T
    Apoptosis; 2017 Sep; 22(9):1098-1115. PubMed ID: 28653223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction.
    Bi X; Yang L; Mancl ME; Barnes BJ
    J Interferon Cytokine Res; 2011 Apr; 31(4):373-82. PubMed ID: 21133648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.
    Tagawa T; Gao S; Koparde VN; Gonzalez M; Spouge JL; Serquiña AP; Lurain K; Ramaswami R; Uldrick TS; Yarchoan R; Ziegelbauer JM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):12805-12810. PubMed ID: 30455306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus.
    King CA; Li X; Barbachano-Guerrero A; Bhaduri-McIntosh S
    J Virol; 2015 Nov; 89(22):11347-55. PubMed ID: 26339061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposi sarcoma herpesvirus-associated cancers and related diseases.
    Goncalves PH; Ziegelbauer J; Uldrick TS; Yarchoan R
    Curr Opin HIV AIDS; 2017 Jan; 12(1):47-56. PubMed ID: 27662501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures.
    Ciufo DM; Cannon JS; Poole LJ; Wu FY; Murray P; Ambinder RF; Hayward GS
    J Virol; 2001 Jun; 75(12):5614-26. PubMed ID: 11356969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
    Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
    Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.